{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T17:27:29Z","timestamp":1786901249680,"version":"build-2736575974"},"reference-count":23,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Teva Branded Pharmaceutical Products R&D LLC."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Huntington's Disease"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Real-world evidence of deutetrabenazine (DTBZ) treatment for Huntington disease (HD)-associated chorea is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a non-interventional, retrospective chart review study from a Huntington's Disease Society of America clinical practice at the University of Alabama at Birmingham (UAB). Patients had a diagnosis of HD-associated chorea, DTBZ initiation (4\/2017\u201312\/2021), \u22652 visits at UAB, and \u22653 months of chorea-related care records post DTBZ initiation. The last Unified HD Rating Scale\u2013Total Maximal Chorea (TMC) score within 3 months prior to DTBZ initiation and first after reaching the last stable dose during follow-up were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 80 eligible patient charts, mean (SD) age was 52.1 (12.6) years and 45 (56.3%) were female. Fifty patients had pre- and post-DTBZ TMC scores and reached a stable dose, including 30 with no prior tetrabenazine (TBZ) or DTBZ exposure, 8 with prior TBZ exposure with a switch to DTBZ after a gap, and 9 with prior TBZ exposure with a switch to DTBZ without a gap. Mean (SD) TMC score decreased (i.e., improved) by 3.7 (4.5), 7.8 (2.8), and 2.1 (4.2), respectively. Overall, 27 (33.8%) patients had \u22651 adverse event recorded between DTBZ initiation and the first visit with a TMC score after reaching their last stable DTBZ dose or DTBZ discontinuation for those without a stable dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This real-world study describes improvements in TMC scores among patients with HD-associated chorea treated with DTBZ, regardless of prior treatment. The observed safety profile supports the known safety profile of DTBZ in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/18796397261468475","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T15:01:40Z","timestamp":1786719700000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment patterns and outcomes of deutetrabenazine in patients with chorea associated with Huntington disease: A retrospective chart review study"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1024-3404","authenticated-orcid":false,"given":"Victor","family":"Sung","sequence":"first","affiliation":[{"name":"Department of Neurology, Division of Movement Disorders, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"White","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Movement Disorders, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hela","family":"Romdhani","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Sethi","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Ayyagari","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayla","family":"Chaijale","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Teva Branded Pharmaceutical Products R&amp;D LLC, West Chester, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4782-8203","authenticated-orcid":false,"given":"Ayelet","family":"Yaari","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0271-3050","authenticated-orcid":false,"given":"Mark Forrest","family":"Gordon","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D LLC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Yang","sequence":"additional","affiliation":[{"name":"Global Health Economics and Outcomes Research, Teva Branded Pharmaceutical Products R&amp;D LLC, West Chester, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinat","family":"Ribalov","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-63233-3.00017-8"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-52014-2.00002-1"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.24"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-018-0312-x"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.36469\/001c.24620"},{"key":"e_1_3_3_7_2","unstructured":"Lundbeck: Xenazine. In: \u00ae (tetrabenazine). Deerfield IL; 2020."},{"key":"e_1_3_3_8_2","unstructured":"Teva Neuroscience Inc: Austedo. In: \u00ae (deutetrabenazine) tablets. Parsippany NJ; 2021."},{"key":"e_1_3_3_9_2","unstructured":"Neurocrine Biosciences Inc: Ingrezza. In: \u00ae (valbenazine) capsules. 2023."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12754"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40734-017-0051-5"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12483"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00309-5"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.1352"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00956-8"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.8655"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-9-62"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00127-8"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01072-4"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318263c443"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2336"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-021-03202-0"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S138828"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25500"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/18796397261468475","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/18796397261468475","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/18796397261468475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T17:16:35Z","timestamp":1786900595000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/18796397261468475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":23,"alternative-id":["10.1177\/18796397261468475"],"URL":"https:\/\/doi.org\/10.1177\/18796397261468475","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"18796397261468475"}}